The release of a new chemical for eyelashes created by Allergan could represent the end for mascara use. The company became extremely popular with its anti-wrinkle drug Botox and its new potential hit, Latisse, might put Allergan even higher.

The new product has already been approved by the Food and Drug Administration (FDA) and will be available across the United States as a prescription medication for enhancing dull or thinning lashes.

Latisse has been developed to treat a condition called hypotrichosis of the eyelashes, which is known as the problem encountered by the people who do not have enough eyelashes. It process is extremely simple, as it only takes a daily appliance to improve the thickness, the length and the color of one’s hairs.

Allergan stated that "Latisse users can expect to experience longer, fuller, and darker eyelashes in as little as eight weeks, with full results in 16 weeks." If the treatment is stopped, the patient’s eyelashes will return over time to their previous appearance with new eyelashes growing in. The company also mentioned that Latisse is the first and only science-based treatment approved by the FDA desinged to deal with this condition.

The company announced that there are some side effects that might occur, such as eye redness and itchiness, a permanet darkening of the eyes’ whites and a darkening of the eyelid skin which may be reversible.

Latisse is expected to ship out all across the US at the beginning of 2009 and a 30-day supply will cost around $120.